IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-01482520.html
   My bibliography  Save this paper

Quality of life, clinical outcomes and safety of early prophylactic ă levothyroxine administration in patients with Graves' hyperthyroidism ă undergoing radioiodine therapy: a randomized controlled study

Author

Listed:
  • David Taïeb

    (Département de radiologie - CHU Nantes - Centre Hospitalier Universitaire de Nantes)

  • Claire Bournaud

    (Département de Médecine Nucléaire - CHU de Lyon - CHU de Lyon)

  • Marie-Claude Eberle
  • Bogdan Catargi

    (CBMN - Chimie et Biologie des Membranes et des Nanoobjets - UB - Université de Bordeaux - ENITAB - École Nationale d'Ingénieurs des Travaux Agricoles - Bordeaux - INC-CNRS - Institut de Chimie - CNRS Chimie - CNRS - Centre National de la Recherche Scientifique)

  • Claire Schvartz

    (FRANCIM - Réseau des registres français du cancer)

  • Marie-Béatrice Cavarec

    (Department of Nuclear Medicine - CHRU Brest - Centre Hospitalier Régional Universitaire de Brest)

  • Isabelle Faugeron
  • Marie-Elisabeth Toubert
  • Danielle Benisvy
  • Cendrine Archange
  • Olivier Mundler

    (TIMONE - Hôpital de la Timone [CHU - APHM], Service de médecine nucléaire [Marseille] - Université de la Méditerranée - Aix-Marseille 2 - APHM - Assistance Publique - Hôpitaux de Marseille - TIMONE - Hôpital de la Timone [CHU - APHM])

  • Philippe Caron

    (Trigone-CIREL - CIREL - Centre Interuniversitaire de Recherche en Education de Lille - ULR 4354 - Université de Lille)

  • Ahmad Esmaeel Abdullah
  • Karine Baumstarck

    (AMU - Aix Marseille Université)

Abstract

Objective: While radioiodine therapy is commonly used for treating ă Graves' disease, a prolonged and clinical hypothyroidism may result in ă disabling symptoms leading to deterioration of quality of life (QoL) of ă patients. Introducing levothyroxine (LT4) treatment in the early ă post-therapeutic period may be an interesting approach to limit this ă phenomenon. ă Methods: A multicenter, prospective, open-label randomized controlled ă trial enrolled 94 patients with Graves' hyperthyroidism randomly ă assigned to the experimental group (n=46) (group A: early prophylactic ă LT4 treatment) or the control group (n=48) (group B: standard ă follow-up). The primary endpoint was the 6-month QoL. The secondary ă endpoints were other QoL scores such as Graves' ophthalmopathy (GO) ă outcomes, thyroid function tests and safety. ă Results: The primary endpoint at 6 months was achieved: the mental ă composite score (MCS) of Short Form 36 (SF-36) was significantly higher ă in group A compared to group B (P=0.009). Four other dimension scores of ă the SF-36 and four dimension scores of the thyroid-specific ă patient-reportedoutcome (ThyPRO) significantly differed between the two ă groups, indicating better QoL in group A. After adjustment for ă variables, the early LT4 administration strategy was found as an ă independent factor for only two scores of SF-36: the MCS and the general ă health (GH) score. There were no differences in GO, final thyroid status ă and changes in the anti-TSH receptor antibodies (TRAbs) levels between ă the two groups. No adverse cardiovascular event was reported. ă Conclusion: Early LT4 administration post-radioactive iodine (RAI) could ă represent a safe potential benefit for patients with regard to QoL. The ă optimal strategy taking into account administered RAI activities and LT4 ă treatment dosage and timing remains to be determined.

Suggested Citation

  • David Taïeb & Claire Bournaud & Marie-Claude Eberle & Bogdan Catargi & Claire Schvartz & Marie-Béatrice Cavarec & Isabelle Faugeron & Marie-Elisabeth Toubert & Danielle Benisvy & Cendrine Archange & O, 2016. "Quality of life, clinical outcomes and safety of early prophylactic ă levothyroxine administration in patients with Graves' hyperthyroidism ă undergoing radioiodine therapy: a randomized controlled st," Post-Print hal-01482520, HAL.
  • Handle: RePEc:hal:journl:hal-01482520
    DOI: 10.1530/EJE-15-1099
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    More about this item

    Keywords

    Quality;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-01482520. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.